Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Blood (2024) 144 (Supplement 1): 4569.3.

https://doi.org/10.1182/blood-2024-200881

Published: 2024

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Seok-Goo Cho, Tae Min Kim, Michal Taszner, Tsai-Yun Chen, Aafia Choudhry, Melanie Ufkin, Amulya Uppala, Ayesha Sabir, Hesham Mohamed, Srikanth Ambati, Emmanuel Bachy

Blood (2024) 144 (Supplement 1): 6302.

https://doi.org/10.1182/blood-2024-200770

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

Blood (2024) 144 (Supplement 1): 4489.

https://doi.org/10.1182/blood-2024-200914

Published: 2024

Journal Articles

The Protective Role of Tubular Epithelial Cells Produced Fms-like Tyrosine Kinase Receptor 3 Ligand in Acute Kidney Injury

Na Li, Yao Guo, Zheqi Wen, Chuyu Xie, Mingcheng Huang, Jiang Shan, Yuming Zhao, Dengyang Zhang, Zhiguang Chang, Liuting Yu, Chi Kong Li, Zhihua Zheng, Zhizhuang Joe Zhao, Yun Chen

Blood (2023) 142 (Supplement 1): 2539.

https://doi.org/10.1182/blood-2023-174317

Published: 2023

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2023-173302

Published: 2023

Journal Articles

The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy

Wenqing Wang, Yan-lai Tang, Zhen Li, Hao Jiang, Chi-Kong Li, Chun Chen, Yun Chen, Hongman Xue

Blood (2023) 142 (Supplement 1): 5823.

https://doi.org/10.1182/blood-2023-187653

Published: 2023

Journal Articles

The Tubular Cells Produce Fms-like Tyrosine Kinase Receptor 3 Ligand to Recover Kidney Function after Acute Kidney Injury Disease

Na Li, Yao Guo, Zhihua Zheng, Yun Chen, Zhizhuang Joe Zhao

Blood (2022) 140 (Supplement 1): 8325.

https://doi.org/10.1182/blood-2022-155704

Published: 2022

Journal Articles

Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial

Wei Xu, Jin-Hua Liang, Li Wang, Xiao-Dong Wang, Guohui Cui, Jianfeng Zhou, Jingyan Xu, Luqun Wang, Rong Liang, Bi-yun Chen, Jian Cheng, Jian-Yong Li

Blood (2022) 140 (Supplement 1): 9484–9486.

https://doi.org/10.1182/blood-2022-157014

Published: 2022

Journal Articles

Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 3292–3293.

https://doi.org/10.1182/blood-2022-165261

Published: 2022

Journal Articles

Niclosamide Inhibits the Growth of Acute Lymphoblastic Leukemia Cells By Increasing Intracellular ROS and Activation of p53-PUMA/NOXA

Junbin Huang, Jing Yang, Yun Chen, Zhizhuang Joe Zhao, Chun Chen

Blood (2022) 140 (Supplement 1): 5917.

https://doi.org/10.1182/blood-2022-168825

Published: 2022

Journal Articles

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Blood (2022) 140 (Supplement 1): 11979–11980.

https://doi.org/10.1182/blood-2022-162488

Published: 2022

Journal Articles

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 8468–8469.

https://doi.org/10.1182/blood-2022-158760

Published: 2022

Journal Articles

Aurora Kinase B/C Inhibitor GSK1070916 Specifically Targets Juvenile Myelomonocytic Leukemia Cells with SHP2(PTPN11) Mutation

Chunxiao He, Dengyang Zhang, Yao Guo, Yuming Zhao, Junbin Huang, Hongman Xue, Chun Chen, Yun Chen, Zhizhuang Joe Zhao

Blood (2022) 140 (Supplement 1): 3092.

https://doi.org/10.1182/blood-2022-168468

Published: 2022

Journal Articles

Establishment of Stable Cell Lines Representing Juvenile Myelomonocytic Leukemia with SHP2 Mutations

Yuming Zhao, Yao Guo, Chunxiao He, Dengyang Zhang, Han Zhong Pei, Ming Yang, Zhiguang Chang, Liuting Yu, Junbin Huang, Hongman Xue, Chun Chen, Zhizhuang Joe Zhao, Yun Chen

Blood (2021) 138 (Supplement 1): 4353.

https://doi.org/10.1182/blood-2021-150007

Published: 2021

Journal Articles

The Ability of CBFβ-SMMHC to Increase RUNX1 Binding Affinity to Target DNA Correlates with Its Leukemogenic Potential

Tao Zhen, Tongyi Dou, Yun Chen, Wei Yang, Jiansen Jiang, Paul P. Liu

Blood (2021) 138 (Supplement 1): 1157.

https://doi.org/10.1182/blood-2021-146193

Published: 2021

Journal Articles

Small Molecule Kinase Inhibitor Sunitinib Specifically Targets Juvenile Myelomonocytic Leukemia Cells with SHP2(PTPN11) Mutation

Chunxiao He, Yuming Zhao, Junbin Huang, Yao Guo, Hongman Xue, Chun Chen, Yun Chen, Zhizhuang Joe Zhao

Blood (2021) 138 (Supplement 1): 3353.

https://doi.org/10.1182/blood-2021-149324

Published: 2021

NARROW

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Trial in Progress: Odronextamab for the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma Following Prior BTK Inhibitor Therapy - a Cohort of the ELM-2 Study

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Outcomes By Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study

The Protective Role of Tubular Epithelial Cells Produced Fms-like Tyrosine Kinase Receptor 3 Ligand in Acute Kidney Injury

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy

The Tubular Cells Produce Fms-like Tyrosine Kinase Receptor 3 Ligand to Recover Kidney Function after Acute Kidney Injury Disease

Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial

Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Niclosamide Inhibits the Growth of Acute Lymphoblastic Leukemia Cells By Increasing Intracellular ROS and Activation of p53-PUMA/NOXA

Clinical Characteristics and Outcomes of Follicular Lymphoma Patients with Extranodal Involvement: Analysis of a Series of 1090 Cases in China

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Aurora Kinase B/C Inhibitor GSK1070916 Specifically Targets Juvenile Myelomonocytic Leukemia Cells with SHP2(PTPN11) Mutation

Establishment of Stable Cell Lines Representing Juvenile Myelomonocytic Leukemia with SHP2 Mutations

The Ability of CBFβ-SMMHC to Increase RUNX1 Binding Affinity to Target DNA Correlates with Its Leukemogenic Potential

Small Molecule Kinase Inhibitor Sunitinib Specifically Targets Juvenile Myelomonocytic Leukemia Cells with SHP2(PTPN11) Mutation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only